Eisai Clinical Trials

Phase II Clinical Study of E7389 for Locally Advanced or Metastatic Breast Cancer


Study Overview

eribulin mesilate
NCT record obsolete. Reporting done in conjuction with study E7389-J081-224 (NCT00965523)
Jan 2008 - Jan 2011
Breast Cancer
Number of Subjects With Adverse Events. [ Time Frame: Every week during treatment and up to 30 days after last dose of study treatment ]

  • Females (age 20 years to 74 years)

  • Completed

  • Phase 2

  • Japan


CSR Synopsis

Download PDF

Lay Summary

No download available

Publication reference citation

Muss H, Cortes J, Vahdat LT, Cardoso F, Twelves C, Wanders J, et al. Eribulin monotherapy in patients
aged 70 years and older with metastatic breast cancer. Oncologist 2014;19(4):318-327.

Data Sharing

ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.

Redacted documents are available upon request for this study.

Document type Availability
Sample CRF
Full CSR